Market Overview:
The global tenofovir alafenamide and its combination drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of HIV/AIDS, rising demand for novel antiretroviral therapies, and growing number of approvals for tenofovir alafenamide-based regimens. Based on type, the global tenofovir alafenamide and its combination drugs market is segmented into five categories: Tenofovir Alafenamide, Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide, Emtricitabine/Rilpivirine/Tenofovir Alafenamide, Emtricitabine/Renofovir Alafenamide, Bictegravir/Emtricitabine/Tenofovid Alaferanide. The Tenofervir alaferanide segment is expected to account for the largest share of the global market in 2018 owing to its high efficacy and safety profile. Based on application, the hospital segment is projected to account for a larger share of the global market in 2018.
Product Definition:
Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir, an antiviral agent with a long history of clinical use. TAF has been demonstrated to be more potent and efficacious than tenofovir disoproxil fumarate (TDF) in preclinical studies.
The combination drugs emtricitabine/tenofovir alafenamide (F/TAF), elvitegravir/cobicistat/tenofovir alafenamide (E/C/TAF), and dolutegravir 50 mg plus abacavir 600 mg plus lamivudine 300 mg tablets are fixed-dose combinations containing TAF. All three regimens are approved by the US Food and Drug Administration for the treatment of HIV-1 infection in adults and adolescents aged ≥12 years weighing ≥35 kg.
Tenofovir Alafenamide:
The global Tenofovir Alafenamide, its usage and growth factor in the market for the tenofovir alafenamide and its combination drugs is expected to grow at a significant rate over the forecast period. The current treatments available for HIV are mainly based on antiretroviral drugs. However, these drugs have several side effects which include abnormal heart rhythms, low blood pressure & cholesterol levels among others.
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide:
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (TAF) is an antiretroviral drug combination used for the treatment of HIV-1 infection. It was approved by the FDA in 2012 under the Food and Drug Administration Safety and Innovation Act as a single-pill, once-a-day medication.
Application Insights:
Based on application, the market is segmented into hospital, clinic and drug center, and others. The other applications include research studies and domestic settings. In 2017, hospital was the largest revenue generating segment owing to high usage of tenofovir alafenamide in treating HIV infection in hospitalized patients.
The combination drugs are used for treatment of HIV-1 infection as well as other viral infections such as hepatitis C virus (HCV) infection or genital herpes simplex virus 2 (HSV-2) that does not respond to standard antiviral therapy. Thus rising prevalence of chronic diseases such as HCV/HIV along with a growing patient base seeking advanced therapies is expected to boost product demand over the forecast period.
Regional Analysis:
In 2017, North America dominated the market with a revenue share of around 49.0%. This is attributed to the fact that this region has one of the highest number of HIV patients worldwide. Moreover, easy availability and high penetration of generic drugs are also supporting growth in this region. The U.S., which is at the forefront in terms of Tenofovir Alafenamide (TAF) consumption, witnessed a significant increase in its treatment rates between 2016 and 2019 as per data published by CDC’s National Center for Health Statistics (NCHS).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to an increasing number of people infected with HIV/AIDS and growing awareness about these medicines among individuals at risk for acquiring HIV infection such as sex workers, men who have had sex with men (MSM), intravenous drug users etc., thus boosting demand for TAF-based therapies across this region.
Growth Factors:
- Increasing incidence of chronic hepatitis B infections: The increasing incidence of chronic hepatitis B infections is a major growth driver for the tenofovir alafenamide and its combination drugs market. According to the World Health Organization, approximately 257 million people are infected with hepatitis B virus (HBV) worldwide, and around 780,000 people die each year from HBV-related diseases. This high prevalence of HBV infection is expected to drive the demand for tenofovir alafenamide and its combination drugs in the coming years.
- Rising awareness about treatment options for chronic hepatitis B: There is a growing awareness among patients and healthcare professionals about the treatment options available for chronic hepatitis B infection. This is likely to boost demand for tenofovir alafenamide and its combination drugs in the coming years.
- Growing number of approvals by regulatory authorities: The number of approvals granted by regulatory authorities for use of tenofovir alafenamide in treating chronic hepatitis B has been increasing over time. This will help fuel growth in this market during the forecast period 2017–2025 .
Scope Of The Report
Report Attributes
Report Details
Report Title
Tenofovir Alafenamide and Its Combination Drugs Market Research Report
By Type
Tenofovir Alafenamide, Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide, Emtricitabine/Rilpivirine/Tenofovir Alafenamide, Emtricitabine/Renofovir Alafenamide, Bictegravir/Emtricitabine/Tenofovir Alafenamide
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Affine Formulations Limited, Beacon Pharmaceuticals, Biocon Limited, Cipla, Flamingo Pharmaceuticals Limited, Gilead Sciences, IPCA Laboratories, Johnson and Johnson, Julphar Bangladesh, Medisist Pharma, Mylan Pharmaceuticals, Natco Pharma, Sun Pharmaceutical Industries, CHIA TAI TIANQING (CTTQ) Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
205
Number of Tables & Figures
144
Customization Available
Yes, the report can be customized as per your need.
Global Tenofovir Alafenamide and Its Combination Drugs Market Report Segments:
The global Tenofovir Alafenamide and Its Combination Drugs market is segmented on the basis of:
Types
Tenofovir Alafenamide, Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide, Emtricitabine/Rilpivirine/Tenofovir Alafenamide, Emtricitabine/Renofovir Alafenamide, Bictegravir/Emtricitabine/Tenofovir Alafenamide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Affine Formulations Limited
- Beacon Pharmaceuticals
- Biocon Limited
- Cipla
- Flamingo Pharmaceuticals Limited
- Gilead Sciences
- IPCA Laboratories
- Johnson and Johnson
- Julphar Bangladesh
- Medisist Pharma
- Mylan Pharmaceuticals
- Natco Pharma
- Sun Pharmaceutical Industries
- CHIA TAI TIANQING (CTTQ) Pharmaceutical
Highlights of The Tenofovir Alafenamide and Its Combination Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tenofovir Alafenamide
- Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
- Emtricitabine/Rilpivirine/Tenofovir Alafenamide
- Emtricitabine/Renofovir Alafenamide
- Bictegravir/Emtricitabine/Tenofovir Alafenamide
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tenofovir Alafenamide and Its Combination Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tenofovir alafenamide is a nucleoside reverse transcriptase inhibitor (NRTI) used to treat HIV infection. Tenofovir alafenamide is also combined with other NRTIs or protease inhibitors to create tenofovir disoproxil fumarate (TDF), emtricitabine/tenofovir disoproxil fumarate (FTC), and etravirin.
Some of the major companies in the tenofovir alafenamide and its combination drugs market are Affine Formulations Limited, Beacon Pharmaceuticals, Biocon Limited, Cipla, Flamingo Pharmaceuticals Limited, Gilead Sciences, IPCA Laboratories, Johnson and Johnson, Julphar Bangladesh, Medisist Pharma, Mylan Pharmaceuticals, Natco Pharma, Sun Pharmaceutical Industries, CHIA TAI TIANQING (CTTQ) Pharmaceutical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tenofovir Alafenamide and Its Combination Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tenofovir Alafenamide and Its Combination Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tenofovir Alafenamide and Its Combination Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tenofovir Alafenamide and Its Combination Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tenofovir Alafenamide and Its Combination Drugs Market Size & Forecast, 2018-2028
4.5.1 Tenofovir Alafenamide and Its Combination Drugs Market Size and Y-o-Y Growth
4.5.2 Tenofovir Alafenamide and Its Combination Drugs Market Absolute $ Opportunity
Chapter 5 Global Tenofovir Alafenamide and Its Combination Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Type
5.2.1 Tenofovir Alafenamide
5.2.2 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
5.2.3 Emtricitabine/Rilpivirine/Tenofovir Alafenamide
5.2.4 Emtricitabine/Renofovir Alafenamide
5.2.5 Bictegravir/Emtricitabine/Tenofovir Alafenamide
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tenofovir Alafenamide and Its Combination Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drug Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tenofovir Alafenamide and Its Combination Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tenofovir Alafenamide and Its Combination Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Type
9.6.1 Tenofovir Alafenamide
9.6.2 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
9.6.3 Emtricitabine/Rilpivirine/Tenofovir Alafenamide
9.6.4 Emtricitabine/Renofovir Alafenamide
9.6.5 Bictegravir/Emtricitabine/Tenofovir Alafenamide
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drug Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tenofovir Alafenamide and Its Combination Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Type
10.6.1 Tenofovir Alafenamide
10.6.2 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
10.6.3 Emtricitabine/Rilpivirine/Tenofovir Alafenamide
10.6.4 Emtricitabine/Renofovir Alafenamide
10.6.5 Bictegravir/Emtricitabine/Tenofovir Alafenamide
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drug Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tenofovir Alafenamide and Its Combination Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Type
11.6.1 Tenofovir Alafenamide
11.6.2 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
11.6.3 Emtricitabine/Rilpivirine/Tenofovir Alafenamide
11.6.4 Emtricitabine/Renofovir Alafenamide
11.6.5 Bictegravir/Emtricitabine/Tenofovir Alafenamide
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drug Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tenofovir Alafenamide and Its Combination Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Type
12.6.1 Tenofovir Alafenamide
12.6.2 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
12.6.3 Emtricitabine/Rilpivirine/Tenofovir Alafenamide
12.6.4 Emtricitabine/Renofovir Alafenamide
12.6.5 Bictegravir/Emtricitabine/Tenofovir Alafenamide
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drug Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tenofovir Alafenamide and Its Combination Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Type
13.6.1 Tenofovir Alafenamide
13.6.2 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
13.6.3 Emtricitabine/Rilpivirine/Tenofovir Alafenamide
13.6.4 Emtricitabine/Renofovir Alafenamide
13.6.5 Bictegravir/Emtricitabine/Tenofovir Alafenamide
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tenofovir Alafenamide and Its Combination Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drug Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tenofovir Alafenamide and Its Combination Drugs Market: Competitive Dashboard
14.2 Global Tenofovir Alafenamide and Its Combination Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Affine Formulations Limited
14.3.2 Beacon Pharmaceuticals
14.3.3 Biocon Limited
14.3.4 Cipla
14.3.5 Flamingo Pharmaceuticals Limited
14.3.6 Gilead Sciences
14.3.7 IPCA Laboratories
14.3.8 Johnson and Johnson
14.3.9 Julphar Bangladesh
14.3.10 Medisist Pharma
14.3.11 Mylan Pharmaceuticals
14.3.12 Natco Pharma
14.3.13 Sun Pharmaceutical Industries
14.3.14 CHIA TAI TIANQING (CTTQ) Pharmaceutical
